DBC-664 in Adult Patients With Solid Tumors Associated

Part of paid clinical trials in Grand Rapids, Michigan.

Sponsor
Duboce Biopharmaceuticals, Inc.
Study ID
NCT07705035
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • DBC-664 — BIOLOGICAL
    DBC-664 will be administered intravenously.

Study Details

DBC-664-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary anti-tumor activity of DBC-664 in patients with endometrial cancer, ovarian cancer, and other advanced solid tumors . This study is divided into 2 parts: Phase-1a Dose Escalation (Part 1), and Phase-1b Dose Expansion (Part 2). In each part, patients who meet specific eligibility criteria will be enrolled.

Key Dates

First listed
Jul 15, 2026
Start date
Jun 15, 2026
Status verified
Jul 2026
Primary completion
Apr 1, 2030
Completion
Apr 1, 2030

Study Design

Enrollment
210 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Part 1 (Dose Escalation)
    Participants will receive DBC-664 to determine the recommended dose for expansion (RDE) regimen.
  • Experimental: Part 2 (Dose Expansion)
    Participants will receive DBC-664 at the RDE as determined in Part 1 of the study to confirm the safety and anti-tumor activity.

Primary Outcome Measure

Safety and Tolerability [ Time Frame: 2 years ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
START MidwestGrand RapidsMichigan49546-
START New JerseyEast BrunswickNew Jersey08816-
START New YorkLake SuccessNew York11402-

Find similar trials in Grand Rapids, MI

By condition
Lung cancerBladder cancer
By specialty
OncologyLung oncologyLung diseaseUrology
By research site
START Midwest· Grand Rapids, MISTART New Jersey· East Brunswick, NJSTART New York· Lake Success, NY

Related Studies